Mitomycin-C as adjunctive treatment of Ocular Surface Squamous Neoplasia

---

Original Article

Author Details : Neha Verma*, Ram Kumar

Volume : 6, Issue : 3, Year : 2020

Article Page : 204-207

https://doi.org/10.18231/j.ijooo.2020.046

Suggest article by email

Get Permission

---

Abstract

Purpose: The aim of this study is to report the efficacy of topical Mitomycin-C (MMC) as adjunctive treatment following primary excision of ocular surface squamous neoplasia (OSSN).
Materials and Methods: After detailed evaluation, 25 eyes in 25 patients with localized primary OSSN were selected in a prospective, interventional study and subjected to primary excision followed by the application of topical 0.04% MMC as an adjunct and thereafter followed up over a 24 month period for signs of any tumor recurrence.
Result: The 25 patients selected with primary OSSN had a mean age of 64(SD 13) with a range of 47-87 years. They underwent surgical excision followed by 3 cycles of freshly prepared 0.04% MMC with 2 weeks on and 2 weeks off for 12weeks.All patients were followed up thereafter at 1 week, 2 weeks, monthly for 6 months and every 3 months for the next 24 months. No tumor recurrence was observed in any of the cases.
Conclusion: Topical MMC has a definite role in preventing tumor recurrence when used as adjunctive treatment following primary surgical excision of OSSN.

Keywords: MitomycinC (MMC), Ocular surface squamous neoplasia (OSSN), Tumor recurrence.

How to cite : Verma N , Kumar R, Mitomycin-C as adjunctive treatment of Ocular Surface Squamous Neoplasia. IP Int J Ocul Oncol Oculoplasty 2020;6(3):204-207

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.